ARTICLE | Finance

Safety equals cash

Why investors put $33.1 million into dermatology play Ziarco

November 17, 2014 8:00 AM UTC

Ziarco Group Ltd.'s combination of preclinical safety data and a better understanding of the mechanism of its lead asset led new investors to provide the dermatology play with enough cash to get two programs through Phase II.

Ziarco's $33.1 million series B round, announced last week, was led by new investors New Enterprise Associates and Lundbeckfond Ventures. New investor Amgen Ventures and existing investors BVF Partners and Pfizer Venture Investments also participated...